Zeiss Medical Technology has received CE mark approval for its CIRRUS PathFinder, a clinical support tool that utilises AI to assist in the interpretation of optical coherence tomography (OCT) scans.
This tool aims to enhance decision-making processes and streamline workflows for clinicians.
The CIRRUS PathFinder employs deep learning algorithms to detect abnormal macular OCT B-scans automatically.
It is part of a new software release that also includes AI-enhanced OCTA image quality and multi-layer segmentation.
According to the company, the PathFinder-equipped CIRRUS system offers rapid image capture with high-definition detail and a broad field of view.
The tool is fully integrated into the clinician's existing workflow, eliminating the need for data export and analysis from external platforms. This integration allows for the simultaneous assessment of numerous scans in real-time.
During the imaging process, the AI system identifies areas that may need further examination, enabling clinicians to concentrate on critical aspects of patient care.
Zeiss Medical Technology ophthalmology strategic business unit head Magnus Reibenspiess said: “The AI decision support capabilities of ZEISS CIRRUS PathFinder help enable faster, more informed and actionable diagnostics for a better clinical and patient experience.”
The latest CIRRUS software update is claimed to enhance OCTA image quality through AI-driven visualisation of vascular structures and improved B-scan averaging.
The additional layer segmentation capabilities are said to further bolster diagnostic accuracy.
Furthermore, the software update introduces enhanced connectivity and security features to address evolving compliance requirements.
The Zeiss CIRRUS platform allows for the seamless integration of OCT data with other diagnostic tools.
The CIRRUS PathFinder is available through licensing in the new software update, which also includes an expanded Reference Database, cybersecurity improvements, multi-layer segmentation and enhanced OCTA visualisation.
This update is currently accessible in selected markets.
In June, China's National Medical Products Administration (NMPA) approved the ZEISS CLARUS 700 retinal imaging system, which includes fluorescein angiography (FA).
